There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on SCYNEXIS (SCYX – Research Report) and Ocuphire Pharma (OCUP – Research Report) with bullish sentiments.
SCYNEXIS (SCYX)
Maxim Group analyst Jason McCarthy maintained a Buy rating on SCYNEXIS yesterday. The company’s shares closed last Thursday at $2.30.
According to TipRanks.com, McCarthy ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for SCYNEXIS with a $11.25 average price target, implying a 425.7% upside from current levels. In a report issued on September 25, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $7.50 price target.
See today’s best-performing stocks on TipRanks >>
Ocuphire Pharma (OCUP)
In a report released today, Sean Kim PhD from JonesTrading reiterated a Buy rating on Ocuphire Pharma, with a price target of $18.00. The company’s shares closed last Thursday at $3.54.
According to TipRanks.com, PhD is a 2-star analyst with an average return of
Currently, the analyst consensus on Ocuphire Pharma is a Moderate Buy with an average price target of $19.00, a 389.7% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $20.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SCYX:
- SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substance
- Scynexis down 29% after announcing Brexafemme recall
- Scynexis recalling Brexafemme from market, placing temporary hold on studies
- Scynexis trading resumes
- Scynexis trading halted, news pending
